Roger Perlmutter, Merck

2013 pay package: $6 million
2012 pay package: (Joined Merck in 2013)
Change: N/A
2013 compensation: $711,538 in salary; $500,000 in bonus; $2.7 million in stock awards; $1.4 million in option awards; $623,700 in non-equity incentive plan compensation; $34,439 in pension value; $16,459 in other compensation

Like Martin Mackay, his Alexion Pharmaceuticals ($ALXN) counterpart, Roger Perlmutter embarked on his second tour of duty last year, taking up the challenge of rescuing Merck's ($MRK) legendary but troubled R&D operation. Perlmutter retired from Amgen ($AMGN) in 2012 after 11 years at the helm of one of the original Big Biotechs, but, about a year into his time away from drug development, the veteran physician-scientist answered the call to help remake the image of one of the industry's most respected institutions.

And he was well compensated for his move. Perlmutter reaped a $500,000 signing bonus upon joining Merck in April 2013, with another half million due a year later if he stuck around. His 9-month pay package of $6 million topped the $5.8 million he made in 2011, his last full year at Amgen, and beat out the 2013 take-home of Sean Harper, his hand-picked successor.

Beyond his $1 million come-hither bonus, Perlmutter picked up a $623,700 award based on what Merck called "the significant progress he has achieved ... in refocusing and reprioritizing Merck's R&D organization and early- and late-stage pipelines."

So far, that has meant shedding a somewhat antiquated approach to product development and about 8,500 jobs along with it, a reprioritization that has resulted in all-hands devotion to Merck's most-promising late-stage assets. MK-3475, the company's fast-progressing cancer immunotherapy, is at the top the pipeline, followed by a two-drug hepatitis C cocktail that, though lagging efforts from Gilead Sciences ($GILD) and AbbVie ($ABBV), is widely expected to compete for physicians' favor once it hits the market. Under Perlmutter's watch, the company has also made a high-risk bet in Alzheimer's disease, a perilous field for pharma, by advancing its BACE-inhibiting MK-8931 into Phase III late last year.

- here's Merck's annual report

For more:
Analysts cheer on Merck's comeback campaign, pumping up blockbuster forecasts
Merck's fast and furious MK-3475 immunotherapy team guns for a quick approval
Struggling Merck slashing 8,500 jobs in major R&D, commercial reorganization
Merck's Perlmutter shares plans for R&D reboot, likes and dislikes

Roger Perlmutter, Merck
Read more on

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.